Status and phase
Conditions
Treatments
About
This is the first in human treatment with ST-920, a recombinant AAV2/6 vector encoding the cDNA for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in humans should, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3. On Day 1, patients will be infused intravenously with a single dose of ST-920 and followed for a period of 52 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Additional Inclusion Criteria:
Renal Cohort:
Cardiac Cohort:
• Left ventricular hypertrophy (LVH) in 2D echocardiography or CMR defined as an end diastolic septum and posterior wall thickness ≥12 mm with no other explanation for LVH, OR presentation with cardiac changes indicative of disease progression such as decreased global longitudinal strain on 2D strain echocardiography or low native T1 mapping on CMR
Exclusion criteria
Additional exclusion criteria for:
Renal cohort:
Cardiac cohort:
Primary purpose
Allocation
Interventional model
Masking
34 participants in 2 patient groups
Loading...
Central trial contact
Patient Advocacy
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal